Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1/2 1

Status

Recruiting 3Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5

Conditions

Breast Neoplasms 13138Neoplasms 10481Carcinoma, Non-Small-Cell Lung 6874Prostatic Neoplasms 6268Colorectal Neoplasms 5948Lung Neoplasms 5105Multiple Myeloma 3577Pancreatic Neoplasms 3563Leukemia, Myeloid, Acute 3510Neoplasm Metastasis 3508Carcinoma, Hepatocellular 3273Ovarian Neoplasms 3168Melanoma 3141Stomach Neoplasms 3057Lymphoma 2983Head and Neck Neoplasms 2604Recurrence 2557Precursor Cell Lymphoblastic Leukemia-Lymphoma 2499Leukemia 2362Colonic Neoplasms 2328Brain Neoplasms 2313Lymphoma, Non-Hodgkin 2269Rectal Neoplasms 2192Uterine Cervical Neoplasms 2191Glioblastoma 2016Leukemia, Lymphocytic, Chronic, B-Cell 1992Carcinoma, Renal Cell 1913Squamous Cell Carcinoma of Head and Neck 1880Lymphoma, Follicular 1848Esophageal Neoplasms 1801

Interventions

Letrozole 2ribociclib 1palbociclib 1abemaciclib 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Fulvestrant 1Epirubicin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
HR+/HER2- Breast Cancer × Clear all
NCT07492641 2026-06-03

KANDELA-302

BeOne Medicines

Phase 3 Recruiting
1,056 enrolled
Breast

HR+/HER2- Breast Cancer

NCT06998407 2026-05-04

AVZO-023-1001

Avenzo Therapeutics, Inc.

Phase 1/2 Recruiting
380 enrolled
Breast

HR+/HER2- Breast Cancer

NCT07130643 2025-08-19

Efficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast Cancer

Hubei Cancer Hospital

Phase 2 Active not recruiting
40 enrolled
Breast

HR+/HER2- Breast Cancer

NCT06860529 2025-06-23

Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

Henan Cancer Hospital

Phase 2 Recruiting
357 enrolled
Breast

HR+/HER2- Breast Cancer

NCT05633914 2023-02-21

Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer

Hunan Cancer Hospital

Phase 2 Unknown
90 enrolled
Breast

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡